The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2025
Journal Information
Share
More article options
Full text access
Is tolvaptan (a vasopressin V2 receptor antagonist) effective in the management of isovolumic and hypervolaemic hypernatremia?
¿El tolvaptán, un antagonista de los receptores de la vasopresina V2, ¿es un tratamiento eficaz para la hiponatremia euvolémica e hipervolémica?
Visits
3970
F. Ortiz
This item has received
Article information




